Kernicterus by glucose-6-phosphate dehydrogenase deficiency: a case report and review of the literature
By Gladys Cossio de Gurrola, Juan José Araúz, Elfilda Durán, Maribel Aguilar-Medina, R. Ramos-Payán, N. García-Magallanes, Gerardo Vaca Pacheco, E. Meraz. Journal of Medical Case Reports, 2008
881 citations recorded by the source corpus.
IntroductionGlucose-6-phosphate dehydrogenase deficiency is an X-linked recessive disease that causes acute or chronic hemolytic anemia and potentially leads to severe jaundice in response to oxidative agents. This deficiency is the most common human innate error of metabolism, affecting more than 400 million people worldwide.Case presentationHere, we present the first documented case of kernicterus in Panama, in a glucose-6-phosphate dehydrogenase-deficient newborn clothed in naphthalene-impregnated garments, resulting in reduced psychomotor development, neurosensory hypoacousia, absence of speech and poor reflex of the pupil to light.ConclusionMutational analysis revealed the glucose-6-phosphate dehydrogenase Mediterranean polymorphic variant, which explained the development of kernicterus after exposition of naphthalene. As the use of naphthalene in stored clothes is a common practice, glucose-6-phosphate dehydrogenase testing in neonatal screening could prevent severe clinical consequences.
Subfields: Clinical Biochemistry, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/4333aa13492e2d60eb1861daefab44380dd3f1a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Kao
- S. Sarin
- Manoj Kumar
- T. Piratvisuth
- Ding‐Shinn Chen
- E. Gane
- G. Lau
- Pei‐Jer Chen
Citations in the corpus
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “In the case of mTOR (mammalian target of rapamycin) inhibitor, everolimus is approved for the treatment of neuroendocrine tumor and renal cell carcinoma (as single-agent), and breast cancer (in combination with hormonal therapy) [580, 581].”
- 22q11.2 deletion syndrome (2015, background): “or crease with or without a faint haemangioma (5).”